Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)
Status:
Completed
Trial end date:
2020-04-08
Target enrollment:
Participant gender:
Summary
The primary objective is to demonstrate that treatment with etelcalcetide (AMG 416) is not
inferior to treatment with cinacalcet for lowering serum intact parathyroid hormone (PTH)
levels by > 30% from baseline among participants with chronic kidney disease (CKD) and
secondary hyperparathyroidism (SHPT) who require management with hemodialysis.